Genmab A/S operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other
miscellaneous service companies in Europe:
Clinigen Group PLC
of UNITED KINGDOM
sales of £456.90 million [US$597.26 million]
of which 45%
was Unlicensed Medicines),
(895.89 million Euros [US$1.05 billion]
of which 93%
was R&D), and
based in UNITED KINGDOM
(£488.50 million [US$638.56 million]
of which 52%
was Operating Genus PIC).
Genmab A/S reported sales of 5.37 billion Danish Kroner (US$845.95 million)
December of 2019.
increase of 77.4%
versus 2018, when the company's sales were 3.03 billion Danish Kroner.
Sales at Genmab A/S have increased during each of the previous five years
(and since 2014, sales have increased a total of 531%).